{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:59:21Z","timestamp":1770818361740,"version":"3.50.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.arbres.2025.09.003","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:42:46Z","timestamp":1758577366000},"page":"133-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune-Mediated Hepatocellular Injury Induced by Elexacaftor\/Tezacaftor\/Ivacaftor Therapy"],"prefix":"10.1016","volume":"62","author":[{"given":"Cindy Stephania","family":"Aponte Guevara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Zamarr\u00f3n De Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Concepci\u00f3n","family":"Prados S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.arbres.2025.09.003_bib0030","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-023-01969-3","article-title":"Aetiology of significant liver test abnormalities in a single-centre cohort of people with cystic fibrosis exposed to elexacaftor\/tezacaftor\/ivacaftor, utilizing the updated RUCAM","volume":"83","author":"Tewkesbury","year":"2023","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.arbres.2025.09.003_bib0035","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcf.2024.01.001","article-title":"Drug-induced liver injury associated with elexacaftor\/tezacaftor\/ivacaftor: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)","volume":"23","author":"Shi","year":"2024","journal-title":"J Cyst Fibros."},{"issue":"3","key":"10.1016\/j.arbres.2025.09.003_bib0040","doi-asserted-by":"crossref","first-page":"211","DOI":"10.18176\/jiaci.0961","article-title":"Protocol for successful desensitization to ivacaftor and elexacaftor\/tezacaftor\/ivacaftor in a delayed hypersensitivity reaction confirmed by the lymphocyte transformation test","volume":"34","author":"Mir-Ihara","year":"2024","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"10.1016\/j.arbres.2025.09.003_bib0045","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.arbres.2025.09.003_bib0050","article-title":"Utility of lymphocyte transformation test for assisting updated Roussel Uclaf causality assessment method in drug-induced liver injury: a case\u2013control study","volume":"13","author":"Rodr\u00edguez","year":"2022","journal-title":"Frontiers in Pharmacology (vol. 13)"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289625003308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289625003308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:19:43Z","timestamp":1770812383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289625003308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0300289625003308"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2025.09.003","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-Mediated Hepatocellular Injury Induced by Elexacaftor\/Tezacaftor\/Ivacaftor Therapy","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2025.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}